Mingfeng Yu

1.6k total citations
53 papers, 1.3k citations indexed

About

Mingfeng Yu is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Mingfeng Yu has authored 53 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 19 papers in Oncology and 16 papers in Organic Chemistry. Recurrent topics in Mingfeng Yu's work include Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Mingfeng Yu is often cited by papers focused on Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Mingfeng Yu collaborates with scholars based in Australia, China and United Kingdom. Mingfeng Yu's co-authors include Shudong Wang, Malika Kumarasiri, Theodosia Teo, Sarah Diab, Robert Milne, Hugo Albrecht, Solomon Tadesse, Sunita K. C. Basnet, Matthew J. Sykes and Frankie Lam and has published in prestigious journals such as PLoS ONE, Journal of Medicinal Chemistry and Inorganic Chemistry.

In The Last Decade

Mingfeng Yu

51 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mingfeng Yu Australia 21 674 443 347 273 167 53 1.3k
Kamil Paruch Czechia 22 891 1.3× 611 1.4× 507 1.5× 265 1.0× 154 0.9× 52 1.7k
James Solowiej United States 8 531 0.8× 402 0.9× 377 1.1× 280 1.0× 92 0.6× 10 1.1k
Jinfeng Luo China 24 626 0.9× 335 0.8× 421 1.2× 158 0.6× 71 0.4× 55 1.4k
Radek Jorda Czechia 22 637 0.9× 352 0.8× 541 1.6× 209 0.8× 83 0.5× 75 1.2k
Lian‐Sheng Li United States 19 1.4k 2.0× 557 1.3× 314 0.9× 241 0.9× 103 0.6× 49 1.9k
Philip Lienau Germany 21 766 1.1× 468 1.1× 433 1.2× 204 0.7× 71 0.4× 37 1.4k
Matthäus Getlik Germany 15 964 1.4× 456 1.0× 324 0.9× 196 0.7× 68 0.4× 18 1.3k
Peter Drueckes Switzerland 15 727 1.1× 290 0.7× 173 0.5× 146 0.5× 87 0.5× 24 1.2k
Frankie Lam Australia 18 479 0.7× 304 0.7× 278 0.8× 194 0.7× 109 0.7× 20 889
Chenyu Tian China 13 738 1.1× 367 0.8× 232 0.7× 183 0.7× 94 0.6× 24 1.4k

Countries citing papers authored by Mingfeng Yu

Since Specialization
Citations

This map shows the geographic impact of Mingfeng Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingfeng Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingfeng Yu more than expected).

Fields of papers citing papers by Mingfeng Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingfeng Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingfeng Yu. The network helps show where Mingfeng Yu may publish in the future.

Co-authorship network of co-authors of Mingfeng Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Mingfeng Yu. A scholar is included among the top collaborators of Mingfeng Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingfeng Yu. Mingfeng Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yu, Mingfeng, Siyun Yang, Linghui Meng, et al.. (2025). PEI-Reinforced GO/g-C3N4 Composite Membrane for Salt Separation. ACS Omega. 10(16). 16620–16632. 1 indexed citations
2.
Yu, Mingfeng, et al.. (2023). Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition. Cancers. 15(4). 1044–1044. 3 indexed citations
3.
Teo, Theodosia, Laychiluh Mekonnen, Yuchao Yang, et al.. (2023). Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation. Molecules. 28(7). 2951–2951. 6 indexed citations
4.
Shen, Jie, Mingfeng Yu, Shuyi Yang, et al.. (2023). Optimization and validation of voxel size-related radiomics variability by combatting batch effect harmonization in pulmonary nodules: a phantom and clinical study. Quantitative Imaging in Medicine and Surgery. 13(9). 6139–6151. 3 indexed citations
5.
Mekonnen, Laychiluh, Sunita K. C. Basnet, Theodosia Teo, et al.. (2023). 2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation. Bioorganic & Medicinal Chemistry. 80. 117158–117158. 13 indexed citations
6.
7.
Yu, Mingfeng, Long Yi, Yuchao Yang, et al.. (2021). Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation. European Journal of Medicinal Chemistry. 218. 113391–113391. 9 indexed citations
8.
Yu, Mingfeng, Theodosia Teo, Yuchao Yang, et al.. (2021). Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry. 214. 113248–113248. 14 indexed citations
9.
Yi, Long, et al.. (2021). Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations. European Journal of Medicinal Chemistry. 213. 113215–113215. 10 indexed citations
10.
Diab, Sarah, Mingfeng Yu, & Shudong Wang. (2020). CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?. Journal of Medicinal Chemistry. 63(14). 7458–7474. 56 indexed citations
11.
Yu, Mingfeng, Sunita K. C. Basnet, Malika Kumarasiri, et al.. (2015). Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure–activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry. 95. 116–126. 31 indexed citations
12.
Teo, Theodosia, Yuchao Yang, Mingfeng Yu, et al.. (2015). An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis. European Journal of Medicinal Chemistry. 103. 539–550. 23 indexed citations
13.
Basnet, Sunita K. C., Sarah Diab, Raffaella M. Schmid, et al.. (2015). Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2. Molecular Pharmacology. 88(5). 935–948. 14 indexed citations
14.
Yu, Mingfeng, Joseph K. Wong, Cyril Tang, et al.. (2015). Efficient deprotection of F-BODIPY derivatives: removal of BF2 using Brønsted acids. Beilstein Journal of Organic Chemistry. 11. 37–41. 28 indexed citations
15.
16.
Diab, Sarah, Malika Kumarasiri, Mingfeng Yu, et al.. (2014). MAP Kinase-Interacting Kinases—Emerging Targets against Cancer. Chemistry & Biology. 21(4). 441–452. 79 indexed citations
17.
Teo, Theodosia, Mingfeng Yu, Yuchao Yang, et al.. (2014). Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells. Cancer Letters. 357(2). 612–623. 38 indexed citations
18.
Diab, Sarah, Theodosia Teo, Malika Kumarasiri, et al.. (2014). Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation. ChemMedChem. 9(5). 962–972. 71 indexed citations
19.
Yu, Mingfeng, Qun Yu, Peter J. Rutledge, & Matthew H. Todd. (2013). A Fluorescent “Allosteric Scorpionand” Complex Visualizes a Biological Recognition Event. ChemBioChem. 14(2). 224–229. 16 indexed citations
20.
Yu, Mingfeng, Ngee Han Lim, Samantha Ellis, et al.. (2013). Incorporation of Bulky and Cationic Cyclam‐Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen. 2(3). 99–105. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kamil Paruch Breakdown of academic impact, for papers by James Solowiej Breakdown of academic impact, for papers by Jinfeng Luo Breakdown of academic impact, for papers by Radek Jorda Breakdown of academic impact, for papers by Lian‐Sheng Li Breakdown of academic impact, for papers by Philip Lienau Breakdown of academic impact, for papers by Matthäus Getlik Breakdown of academic impact, for papers by Peter Drueckes Breakdown of academic impact, for papers by Frankie Lam Breakdown of academic impact, for papers by Chenyu Tian
Rankless by CCL
2026